Targeted therapies in sarcomas: challenging the challenge
Juan Martín Liberal1, Laura Lagares-Tena, Miguel Sáinz-Jaspeado
1Laboratori d'Oncología Molecular, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
Abstract:
Sarcomas are a heterogeneous group of mesenchymal malignancies that very often lead to death. Nowadays, chemotherapy is the only available treatment for most sarcomas but there are few active drugs and clinical results still remain very poor. Thus, there is an imperious need to find new therapeutic alternatives in order to improve sarcoma patient's outcome. During the last years, there have been described a number of new molecular pathways that have allowed us to know more about cancer biology and tumorigenesis. Sarcomas are one of the tumors in which more advances have been made. Identification of specific chromosomal translocations, some important pathways characterization such as mTOR pathway or the insulin-like growth factor pathway, the stunning development in angiogenesis knowledge, and brand new agents like viruses have lead to the development of new therapeutic options with promising results. This paper makes an exhaustive review of preclinical and clinical evidence of the most recent targeted therapies in sarcomas and provides a future view of treatments that may lead to improve prognosis of patients affected with this disease.
Insights
New targeted therapies show promise for treating deadly sarcomas, offering hope beyond traditional chemotherapy. This review covers recent advances and future directions for improving patient outcomes in sarcoma treatment.
Area of Science:
- Oncology
- Cancer Biology
- Translational Medicine
Background:
- Sarcomas are aggressive mesenchymal malignancies with poor outcomes using current chemotherapy.
- There is a critical need for novel therapeutic strategies to improve sarcoma patient survival.
- Recent advances in understanding sarcoma biology have identified new molecular targets.
Purpose of the Study:
- To conduct an exhaustive review of preclinical and clinical evidence for novel targeted therapies in sarcomas.
- To explore emerging therapeutic options and their potential to improve sarcoma patient prognosis.
- To provide a future outlook on advanced sarcoma treatment strategies.
Main Methods:
- Comprehensive literature review of preclinical studies on targeted sarcoma therapies.
- Analysis of clinical trial data for recently developed targeted agents in sarcoma treatment.
- Synthesis of current knowledge on molecular pathways and novel therapeutic approaches.
Main Results:
- Identification of key molecular pathways (e.g., mTOR, IGF) driving sarcoma development.
- Emerging targeted therapies demonstrate promising preclinical and early clinical results.
- Advances in understanding angiogenesis and oncolytic viruses offer new treatment avenues.
Conclusions:
- Targeted therapies represent a significant advancement in sarcoma treatment beyond conventional chemotherapy.
- Continued research into molecular pathways and novel agents is crucial for improving sarcoma patient outcomes.
- Future sarcoma treatment will likely involve personalized approaches based on molecular profiling.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...